Disrupted circadian rhythms in cognitively normal adults have been found to be associated with higher subsequent amyloid-beta levels, according to recent prospective data. This relationship was particularly strong in individuals who carry the APOE4 gene. The findings remained consistent even after excluding participants with baseline Alzheimer’s pathology. Researchers conducted a study involving 319 participants in
Health
The recent announcement by the FDA expanding the indication of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) to include treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) is a significant milestone in the field of neurology. This decision provides hope to patients suffering from this rare and debilitating immune-mediated neuromuscular disorder by offering a new,
A recent study conducted by David Preiss, MBChB, PhD, at the University of Oxford has shown that fenofibrate, a cholesterol drug, can reduce the progression of early diabetic retinopathy or maculopathy among diabetes patients. The trial demonstrated a 27% reduction in disease progression over 4 years compared to a placebo. This finding is significant as
The drug sample that was recently tested contained a dangerous cocktail of substances, including multiple nitazenes, fentanyl analogues, xylazine, diphenhydramine, caffeine, and medetomidine. The mention of medetomidine in particular caught my attention, as it has been linked to a recent surge in overdoses. While opioid overdoses are unfortunately nothing new to me, this particular case
Roy Herbst, MD, PhD, of Yale Cancer Center, recently discussed groundbreaking new data surrounding osimertinib (Tagrisso) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The LAURA and ADAURA trials have provided exciting insights into the potential of osimertinib in improving progression-free survival for patients with stage III NSCLC. The findings from the ADAURA trial
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect various organs in the body, including the kidneys. A recent analysis of medical records has suggested that patients with SLE who were taking metformin had lower rates of lupus nephritis, chronic kidney disease (CKD), and major adverse cardiovascular events (MACE) compared to those
Rheumatoid arthritis (RA) patients face an increased risk of major adverse cardiovascular events (MACE) and mortality. Standard risk factors do not fully account for these risks in RA patients, prompting researchers to investigate alternative measures such as high-sensitivity cardiac troponin T (hs-cTnT) testing. A recent study conducted at Brigham and Women’s Hospital in Boston revealed
A recent study sheds light on the missed opportunities in treating drug overdose survivors who are covered by the Medicare program. The study highlights the challenges in managing chronic pain and addiction, demonstrating a significant gap in the provision of holistic care for this vulnerable population. According to Brian Hurley, MD, president of the American
Recently, the FDA has approved two new immunotherapy-chemotherapy options for patients with primary advanced or recurrent endometrial cancer. One of these options is the PD-1-directed immune checkpoint inhibitor pembrolizumab, also known as Keytruda. This drug has been approved in combination with carboplatin and paclitaxel for patients with either mismatch repair (MMR)-deficient or MMR-proficient disease. The
In the field of medicine, it is crucial to critically analyze statements made by healthcare professionals to ensure accuracy and reliability. Misinterpretation or misunderstanding of medical information can have serious consequences for patients and the overall healthcare system. When examining quotes such as “The only side effects are good ones” by Dean Ornish, MD, it